Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Prothena Corporation PLC | PRTA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 20.55 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 20.55 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 19.65 - 79.65 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 20.55 | USD |
Prothena Corporation PLC Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.1B | 53.72M | - | 91.37M | -147.03M | -2.74 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Prothena News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PRTA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 20.56 | 21.79 | 19.65 | 20.83 | 436,831 | -0.01 | -0.05% |
| 1 Month | 24.92 | 26.36 | 19.65 | 22.55 | 520,562 | -4.37 | -17.54% |
| 3 Months | 26.92 | 31.03 | 19.65 | 25.85 | 637,337 | -6.37 | -23.66% |
| 6 Months | 37.78 | 41.545 | 19.65 | 31.82 | 777,124 | -17.23 | -45.61% |
| 1 Year | 54.01 | 79.65 | 19.65 | 42.73 | 624,912 | -33.46 | -61.95% |
| 3 Years | 23.90 | 79.749 | 19.65 | 45.27 | 527,594 | -3.35 | -14.02% |
| 5 Years | 10.86 | 79.749 | 6.44 | 37.02 | 425,991 | 9.69 | 89.23% |
Prothena Description
| Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). |
